ImmuCell Corporation (ICCC)

In January 2026, ImmuCell announced preliminary sales results for Q4 and full-year 2025, with a positive stock reaction following the sales results and news of a strategic refocus. In December 2025, the company received an FDA Incomplete Letter for Re-Tain®, leading to a strategic shift towards First Defense® and a non-cash impairment write-down, with improved investor sentiment. In November 2025, Q3 2025 sales were announced, leading to deteriorated investor sentiment, and Olivier te Boekhorst was appointed as the new President and CEO. Preliminary sales results for Q3 2025 were announced in October 2025. The selection of the next President and CEO was announced in September 2025. In August 2025, Q2 2025 sales were announced, showing an increase in product sales, and the company reported eliminating its backlog of orders. Preliminary sales for Q2 2025 were reported in July 2025.

Demand for ImmuCell's products, particularly the First Defense® line, exhibits seasonality, with sales generally lower in the third quarter. The company strategically builds inventory during this period to prepare for the peak selling season, which typically occurs towards the end of the year and extends into the first quarter.

ImmuCell Corp. is an animal health company focused on developing, manufacturing, and selling products that enhance the health and productivity of cows within the dairy and beef industries, operating in the biotechnology industry. Its primary product line is First Defense®, an orally delivered preventive for scours in newborn calves. The company was also developing Re-Tain®, an FDA-regulated product intended to treat subclinical mastitis in lactating dairy cows, but investment has been paused following an FDA Incomplete Letter.

ImmuCell Corp. is headquartered in Portland, Maine, USA, and operates both domestically and internationally. Domestic sales constitute a significant portion of its revenue and have shown growth, while international sales have recently experienced a downturn.

ImmuCell's brand reputation has been influenced by both positive developments and challenges. The company reported strong preliminary revenue for fiscal year 2025, and its Tri-Shield product line has shown strong expansion. The First Defense® product line holds a leading position in the U.S. market for scour-prevention. The company has also demonstrated operational recovery from 2023 to 2025. A major setback was the FDA Incomplete Letter for Re-Tain®, leading to the cessation of further investment in the product. The company has also experienced a downturn in international sales and a decline in sales of its Dual-Force® and other products.

Institutional investors hold between 13.47% and 14.19% of ImmuCell's stock, individual insiders own 21.29% to 28.1%, and retail investors account for 64.52%. Major institutional owners include Vanguard Group Inc and Renaissance Technologies LLC. Norman H. Pessin is the largest individual insider shareholder. Insider buying has outpaced selling in the past three months.